Mipragoside (molecular weight 1574) is the iso propylic ester of a monosialotetrahexosyl ganglioside (GM ! ), a natural ganglioside. Gangliosides are complex biological molecules which consist of a short carbohydrate chain with one or more sialic acid residues attached to a double lyphophilic tail formed by the aminoa1cohol sphingosin and a fatty acid. These substances are natural components of the outer surface of the cell membrane, particularly abundant in the nervous system. Exogenously administered, gangliosides have been shown to enhance recovery after central nervous system injury. ! Recent studies suggest that the esterification of GM!, through which Mipragoside is obtained,
SUMMARY
Mipragoside (molecular weight 1574) is the iso propylic ester of a monosialotetrahexosyl ganglioside (GM ! ), a natural ganglioside. Gangliosides are complex biological molecules which consist of a short carbohydrate chain with one or more sialic acid residues attached to a double lyphophilic tail formed by the aminoa1cohol sphingosin and a fatty acid. These substances are natural components of the outer surface of the cell membrane, particularly abundant in the nervous system. Exogenously administered, gangliosides have been shown to enhance recovery after central nervous system injury. ! Recent studies suggest that the esterification of GM!, through which Mipragoside is obtained, 4 In humans topical application of Mipragoside ophthalmic gel significantly reduced the inflamma tory cell recruitment in the tear fluid following specific allergen challenge in patients with ocular hay fever. 5 Vernal keratoconjunctivitis (VKC) is a chronic and recurrent ocular disease characterised by a marked cellular inflammatory infiltration in which mast cells, eosinophils, lymphocytes and basophils, as well as their derived soluble mediators, have a major pathogenetic role. 6 The purpose of the study was to investigate in a double-masked randomised study whether Miprago side 0.5% ophthalmic gel is effective in the treatment of VKC when compared with placebo.
MATERIALS AND METHODS
A double-masked randomised study was performed in 24 (21 male, 3 female) patients with a history of VKC (Table I) . Their mean age was 10±3.5 years, range 5-20 years. Diagnosis was based on clinical examination, history of seasonal exacerbation of the disease and the presence of eosinophils in a conjunctival scrape. All patients had only the palpebral and not the limbal form of VKC. Only 2 patients had giant papillae in their upper tarsal conjunctiva.
The following ocular signs and symptoms were considered: itching, burning, photophobia, grittiness, discharge, tearing and hyperaemia. Each sign and symptom was evaluated and scored from 0 to 4+ as follows: 0, absent; 1+, mild; 2+, moderate; 3+, severe;
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Patients who had other eye diseases, wore contact lens or were taking other anti-inflammatory thera pies were excluded from the study. No other topical medications were allowed during the trial and all patients were without topical medication for at least 1 week before the beginning of the study. Formal consent was obtained from all patients or their parents before starting the treatment.
Each patient received either Mipragoside 0.5% ophthalmic gel (Mipragoside, sorbitol, carboxypoly methylene, purified water, sodium hydroxide qs to pH 6.5; manufactured by Fidia, Abano Terme, Italy) or placebo (the same compounds without Mipragoside) unidose, 4 times a day for 2 weeks. All patients had a week of washout with placebo before the treatment. Clinical signs and symptoms were assessed at entry, after the baseline week and after 1 and 2 weeks of treatment. An overall assessment at the end of treatment was performed by the clinicians in the study and graded from 1 (fully controlled) to 7 (worse).
Non-parametric (Mann-Whitney U-test and Krus kal-Wallis test) statistical analysis was performed. A probability of 0.05 or less was considered statistically significan t.
RESULTS
Twenty patients (11 treated with Mipragoside 0.5% ophthalmic gel and 9 with placebo) completed the clinical trial and were considered for statistical analysis (Table I) . Four patients withdrew from the study; 3 patients (2 in the placebo group and 1 in the Mipragoside group) for non-cooperation and 1 patient (placebo group) for treatment failure. The total mean score at the end of baseline was 10.8±3.7 for patients in Mipragoside group and 13.5±3.7 for (Table  II) , itching (p = 0.01) (Table II) and grittiness (p = 0.0001) compared with the placebo. At the end of treatment (14 days), Mipragoside significantly reduced hyperaemia (p = 0.0006) (Table II) , itching (p = 0.0001) (Table II) , grittiness (p = 0.001), dis charge (p = 0.01) and tearing (p = 0.0001) compared with the placebo. No statistical differences were observed for any symptom between the time of entry into the study and the end of the baseline period (day 0).
According to the clinicians involved, Mipragoside produced a marked improvement in the overall condition of 10 patients (91 %) and a little improve ment in 1 patient (9%), while in the placebo group a mild clinical improvement was observed in 6 patients (69%) and no change in 3 patients (33 %). The difference between groups was statistically significant (p<0.0001).
DISCUSSION
Our study shows that Mipragoside is more effective than placebo in reducing the ocular signs and symptoms of patients with mild to moderate VKC.
Gangliosides are components of all cell mem branes and are particularly abundant in the nervous system, where they induce neurogenesis and exhibit a trophic effect on nerve cell growth in vitro. In vivo, a particular ganglioside, GMb reduces cerebral oedema and accelerates recovery from injury to the peripheral and central nervous system. 1 Gangliosides are potent immunomodulatory agents capable of inhibiting the mitogenic activation of lymphocytes or the stimulatory action of interleukin-2 in vitro. 7 -9 Moreover, gangliosides have an inhibitory action on cells and inflammatory mediators in both experi mental animals and humans?· 3 Although their mechanism of action in extraneuronal cells has not been defined, it seems likely that it is due to activation of phospholipase C, which leads to the generation of inositol-l,4,5-triphosphate and diacyl glycerol and an elevation of intracellular Ca 2 +. A rise in the intracellular concentration of Ca 2 + serves to initiate exocytosis with a mechanism that probably involves the activation of Ca 2 +/calmodulin-depen dent protein kinases and protein kinase c. 4 Recent studies have shown that Mipragoside acts by stabilising mast cell membranes, probably because it interferes 2 with the transmembranous calcium fluxes.
The presence of inflammatory cells and mediators is a constant feature of VKC. Mast cells, eosinophils, neutrophils and lymphocytes infiltrate the conjuncti val mucosa and have an active role in the allergic inflammation. 6 The efficacy of topical Mipragoside on the ocular signs and symptoms of patients with VKC could be due to an anti-inflammatory action on cells and mediators of this disease.
In conclusion, Mipragoside ophthalmic gel seems to be effective in the treatment of VKC and could be a valid therapeutic alternative to sodium cromogly cate.
